ZUMA-23: A first-line CAR-T trial in LBCL, presented at ASCO 2023
The Phase 3 ZUMA-23 trial will evaluate the efficacy of axi-cel as a first-line treatment for LBCL patients. This study is currently enrolling at Australian sites.
axicabtagene ciloleucel
ZUMA-7 update at ASCO 2023
Updated survival analyses were presented for ZUMA-7 at ASCO 2023
Axi-cel in PCNSL and SCNSL
This study investigated the safety and efficacy of axi-cel in 9 patients with PCNSL and SCNSL. The authors reported no increased risk of high-grade ICANS, cerebral oedema, or other neurologic events; Complete response rate was 86%.
CAR-T therapy for the elderly – What does recent real-world data say?
The safety and efficacy of CAR-T therapy in elderly patients is of interest due to frailty with an accumulation of comorbidities and geriatric syndromes. Recent European real-world data regarding the safety and efficacy for CAR-T therapy in elderly patients was presented at EHA 2022.
Real-world comparison of axi-cel and tisa-cel in DLBCL
Real-world evidence data have confirmed the efficacy and safety of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel). This updated PSM analysis aimed to assess outcomes in a larger cohort of patients with DLBCL over a longer follow-up period.